144 related articles for article (PubMed ID: 37075624)
21. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
22. The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage.
Jin C; Einig E; Xu W; Kollampally RB; Schlosser A; Flentje M; Popov N
Nucleic Acids Res; 2024 Apr; 52(6):3011-3030. PubMed ID: 38227944
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-216b suppresses the cell growth of hepatocellular carcinoma by inhibiting Ubiquitin-specific peptidase 28 expression.
Zhang JF
Kaohsiung J Med Sci; 2020 Jun; 36(6):423-428. PubMed ID: 32053284
[TBL] [Abstract][Full Text] [Related]
24. Maintaining protein stability of ∆Np63 via USP28 is required by squamous cancer cells.
Prieto-Garcia C; Hartmann O; Reissland M; Braun F; Fischer T; Walz S; Schülein-Völk C; Eilers U; Ade CP; Calzado MA; Orian A; Maric HM; Münch C; Rosenfeldt M; Eilers M; Diefenbacher ME
EMBO Mol Med; 2020 Apr; 12(4):e11101. PubMed ID: 32128997
[TBL] [Abstract][Full Text] [Related]
25. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
De Smaele E; Ferretti E; Gulino A
Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
[TBL] [Abstract][Full Text] [Related]
26. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
28. The N-terminal ubiquitin-binding region of ubiquitin-specific protease 28 modulates its deubiquitination function: NMR structural and mechanistic insights.
Wen Y; Shi L; Ding Y; Cui R; He WT; Hu HY; Zhang N
Biochem J; 2015 Oct; 471(2):155-65. PubMed ID: 26268556
[TBL] [Abstract][Full Text] [Related]
29. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
30. USP28 is a potential prognostic marker for bladder cancer.
Guo G; Xu Y; Gong M; Cao Y; An R
Tumour Biol; 2014 May; 35(5):4017-22. PubMed ID: 24347490
[TBL] [Abstract][Full Text] [Related]
31. The concomitant use of USP28 and p53 to predict the progression of urothelial carcinoma of the bladder.
Devrim T; Ataç F; Devrim AK; Balcı M
Pathol Res Pract; 2020 Jan; 216(1):152774. PubMed ID: 31822365
[TBL] [Abstract][Full Text] [Related]
32. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
33. ¹H, ¹³C and ¹⁵N backbone and side-chain resonance assignments of the N-terminal ubiquitin-binding domains of the human deubiquitinase Usp28.
Wen Y; Cui R; Zhang H; Zhang N
Biomol NMR Assign; 2014 Oct; 8(2):251-4. PubMed ID: 23754699
[TBL] [Abstract][Full Text] [Related]
34. Differential Oligomerization of the Deubiquitinases USP25 and USP28 Regulates Their Activities.
Sauer F; Klemm T; Kollampally RB; Tessmer I; Nair RK; Popov N; Kisker C
Mol Cell; 2019 May; 74(3):421-435.e10. PubMed ID: 30926243
[TBL] [Abstract][Full Text] [Related]
35. Identification of the deubiquitinase USP28 as a novel molecular therapeutic target of ovarian cancer.
Shen J; Xie M; Xu Y; Qian Q; Qiu T; Shi W; Ren D; Ji J; Huang J
Biochem Biophys Res Commun; 2023 Jan; 638():184-191. PubMed ID: 36462492
[TBL] [Abstract][Full Text] [Related]
36. Ubiquitin-specific protease 28 deubiquitinates TCF7L2 to govern the action of the Wnt signaling pathway in hepatic carcinoma.
Sun X; Cai M; Wu L; Zhen X; Chen Y; Peng J; Han S; Zhang P
Cancer Sci; 2022 Oct; 113(10):3463-3475. PubMed ID: 35880246
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth.
Zhang L; Xu B; Qiang Y; Huang H; Wang C; Li D; Qian J
J Cell Mol Med; 2015 Apr; 19(4):799-805. PubMed ID: 25656529
[TBL] [Abstract][Full Text] [Related]
38. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
39. Ubiquitin-specific peptidase 28 enhances STAT3 signaling and promotes cell growth in non-small-cell lung cancer.
Li P; Huang Z; Wang J; Chen W; Huang J
Onco Targets Ther; 2019; 12():1603-1611. PubMed ID: 30881015
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
